Company News
Talley Group receive FDA clearance to market Venturi™ system in the United States
Talley Group are delighted to announce that the Venturi™ Negative Pressure Wound Therapy system has received clearance from the FDA.
Talley Group CEO Chris Evans stated
With over 2 years of European experience in the NPWT arena, the FDA’s clearance to market the product in the US clearly demonstrates the International attention the Venturi™ product range has attracted. We are looking forward to working with our partners to develop the exciting business opportunities
Continue Reading | Posted: Wednesday, July 16th, 2008